ConductScience.org, home

Trial · NCT00511355

Results by group248

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Serum Concentration of Prothrombin Fragments 1 + 2NOMAC-E2Baseline (n=60 NOMAC-E2; n=58 LNG-EE)0.18Standard Deviation 0.20nmol/L
Serum Concentration of Prothrombin Fragments 1 + 2LNG-EEBaseline (n=60 NOMAC-E2; n=58 LNG-EE)0.19Standard Deviation 0.08nmol/L
Serum Concentration of Prothrombin Fragments 1 + 2NOMAC-E2Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)0.31Standard Deviation 1.06nmol/L
Serum Concentration of Prothrombin Fragments 1 + 2LNG-EECycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)0.42Standard Deviation 1.17nmol/L
Serum Concentration of D-DimerNOMAC-E2Baseline (n=60; NOMAC-E2; n=58)0.21Standard Deviation 0.16mg/L Fibrinogen Equivalent Units (FEU)
Serum Concentration of D-DimerLNG-EEBaseline (n=60; NOMAC-E2; n=58)0.19Standard Deviation 0.14mg/L Fibrinogen Equivalent Units (FEU)
Serum Concentration of D-DimerNOMAC-E2Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)0.18Standard Deviation 0.14mg/L Fibrinogen Equivalent Units (FEU)
Serum Concentration of D-DimerLNG-EECycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)0.26Standard Deviation 0.21mg/L Fibrinogen Equivalent Units (FEU)
Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based)NOMAC-E2Baseline (n=59 NOMAC-E2; n=58 LNG-EE)0.80Standard Deviation 0.33Ratio
Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based)LNG-EEBaseline (n=59 NOMAC-E2; n=58 LNG-EE)0.83Standard Deviation 0.40Ratio
Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based)NOMAC-E2Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)1.14Standard Deviation 0.45Ratio
Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based)LNG-EECycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)1.99Standard Deviation 0.76Ratio
Serum Concentration of Clotting Factor VIIaNOMAC-E2Baseline (n=60 NOMAC-E2; n=58 LNG-EE)84Standard Deviation 32U/L
Serum Concentration of Clotting Factor VIIaLNG-EEBaseline (n=60 NOMAC-E2; n=58 LNG-EE)85Standard Deviation 37U/L
Serum Concentration of Clotting Factor VIIaNOMAC-E2Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)118Standard Deviation 180U/L
Serum Concentration of Clotting Factor VIIaLNG-EECycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)98Standard Deviation 66U/L
Serum Concentration of Clotting Factor VIIcNOMAC-E2Baseline (n=60 NOMAC-E2; n=58 LNG-EE)105Standard Deviation 24Percent of normal
Serum Concentration of Clotting Factor VIIcLNG-EEBaseline (n=60 NOMAC-E2; n=58 LNG-EE)105Standard Deviation 22Percent of normal
Serum Concentration of Clotting Factor VIIcNOMAC-E2Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)109Standard Deviation 31Percent of normal
Serum Concentration of Clotting Factor VIIcLNG-EECycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)96Standard Deviation 25Percent of normal

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00511355/results